Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is the most common neurodegenerative disease. Prior to 2017, National Medical Products Administration approved only four drugs to treat Alzheimer's disease, including three cholinesterase inhibitors and one N-methyl-D-aspartate receptor antagonist. We queried ClinicalTrials.gov to better understand Alzheimer's drug development over the past 5 years and found 16 promising candidates that have entered late-stage trials and analyzed their impact on clinical treatment of Alzheimer's disease in China. The 16 compounds selected include disease-modifying therapies and symptomatic therapies. The research and development pipeline now focuses on disease-modifying therapies such as gantenerumab, aducanumab, ALZ-801, ALZT-OP1, donanemab, lecanemab, simufilam, NE3107, semaglutide, and GV-971, which could put an end to the situation where Alzheimer's patients in China have no effective treatment alternatives. The reuse of drugs or combinations currently under investigation for the psychiatric treatment of Alzheimer's disease, including AXS-05, AVP-786, nabilone, brexpiprazole, methylphenidate, and pimavanserin, could provide physicians with additional treatment options. Although most of these drugs have not been explored in China yet, due to the current development trend in this field in China, it is expected that China will be involved in research on these drugs in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In interim results from its phase II trial (NCT04693520), the drug lowered biomarker levels and showed the potential to slow the decline in memory and learning abilities in early AD patients carrying the APOE4 gene (either APOE4/4 or APOE3/4).425”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [425]
The cited source says what the claim attributes to it.
In the citing paper
“Brexpiprazole (11), commonly prescribed for depression and schizophrenia, targets serotonin, dopamine, and norepinephrine receptors. It is known to help mitigate agitation in individuals with AD.425–427”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [425]
The cited source says what the claim attributes to it.
In the citing paper
“NE3107 (25, formerly HE3286) is a small insulin sensitizer that inhibits inflammation.425”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [425]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 3×
“Despite mixed secondary outcomes, donanemab has a better composite score for cognition and ability to perform activities of daily living than placebo (35).”
BackgroundInfluentialWang, X., Sun, G., Feng, T., Zhang, J., Huang, X., Wang, T., Xie, Z., Chu, X., Yang, J., Wang, H., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0216-x · Cited by 1,144 · cited 2×
“In sodium oligomannatetreated mice, there was a reduction in brain Th1 cells, microglial activation, and various brain cytokines, as well as a reduction in Aβ plaque aggregation and tau phosphorylation, as well as an improvement in discrimination learning (52).”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · cited 1×
“GLP-1 is a hormone produced in the gut that stimulates the release of insulin and improves insulin sensitivity by activating receptors in the pancreas, liver, and gut (41).”
BackgroundBurns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 1×
“It also enhances synaptic plasticity, cognition, and cell survival in the hippocampus nucleus (44).”
BackgroundSwanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · cited 3×
“However, the 12-month primary endpoint was not met (31).”
BackgroundMethodInfluentialKellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832 · cited 1×
“According to prior studies, insulin resistance has been linked to neurodegeneration (88).”
BackgroundSalloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619 · cited 2×
“%) in the 10 mg/kg group in the phase 3 randomized clinical trials (RCTs) of aducanumab EMERGE (NCT02484547) and ENGAGE (NCT02477800) (13).”
BackgroundAlzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · cited 7×
“Tau biology adds to the list of potentially relevant targets for DMT (89).”
BackgroundInfluentialBohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 1×
“In vivo, gantenerumab suppresses oligomeric Aβ42’s neurotoxic effects (23).”
BackgroundA Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420 · cited 1×
“By lowering AChE activity, these medications temporarily halt the loss of cognitive function, resulting in increased ACh levels and enhanced brain function (84).”
BackgroundMaeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372 · cited 1×
“Brexpiprazole Brexpiprazole is a unique third-generation antipsychotic that functions as a partial agonist for dopamine D2 receptors, a partial agonist for serotonin 5-HT1A receptors, an antagonist for serotonin 5-HT2A/5-HT2B receptors, and a partial antagonist for noradrenaline α1B/α2C receptors (Figure 4D) (65).”
BackgroundStructural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 365 · cited 1×
“The chemical structure of aducanumab is not available online, but studies have found that it binds to the N-terminus of Aβ in an extended conformation (11).”
BackgroundTolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00663-w · Cited by 354 · cited 2×
“Lecanemab is distinct in that it is intended for patients of all genotypes, including APOE4/4 homozygotes (19).”
BackgroundOn the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
Hacksell, U., Burstein, E. S., McFarland, K., Mills, R. G., & Williams, H. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1293-3 · Cited by 297 · cited 1×
“It is a selective inverse agonist/antagonist of the 5-HT2A receptor with little affinity for the 5-HT2C receptor and no affinity for dopaminergic, muscarinic, histaminergic, or adrenergic receptors (77).”
BackgroundLogovinsky, V., Satlin, A., Lai, R., Swanson, C., Kaplow, J., Osswald, G., Basun, H., & Lannfelt, L. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0181-2 · Cited by 285 · cited 1×
“In all cases, lecanemab was extremely safe (30).”
BackgroundTucker, S., Möller, C., Tegerstedt, K., Lord, A., Laudon, H., Sjödahl, J., Söderberg, L., Spens, E., Sahlin, C., Waara, E. R., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140741 · Cited by 272 · cited 1×
“brain (42% less) and CSF in tg-ArcSwe mice (53% less) (27).”
BackgroundTolar, M., Hey, J., Power, A., & Abushakra, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126355 · Cited by 243 · cited 4×
“The target population of lecanemab is early AD patients of all genotypes and APOE4 carriers (10).”
BackgroundInfluentialXiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00795-7 · Cited by 224 · cited 1×
“The results of a 36-week experiment revealed that GV-971 displayed high efficacy in improving cognition, with persistent improvement throughout all observation periods (55).”
BackgroundAn Antidepressant Decreases CSF Aβ Production in Healthy Individuals and in Transgenic AD Mice
Sheline, Y. I., West, T., Yarasheski, K., Swarm, R., Jasielec, M. S., Fisher, J. R., Ficker, W. D., Yan, P., Xiong, C., Frederiksen, C., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008169 · Cited by 223 · cited 1×
“A prior study found that serotonin signaling attenuated Aβ in vitro and in animal models of AD (79).”
BackgroundKlein, G., Delmar, P., Voyle, N., Rehal, S., Hofmann, C., Abi-Saab, D., Andjelkovic, M., Ristic, S., Wang, G., Bateman, R., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0559-z · Cited by 212 · cited 2×
“At 2 years, 51% patients receiving up to 1,200mg of gantenerumab had PET amyloid levels consistent with sparse to non-neuritic Aβ (25).”
BackgroundHölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.040 · Cited by 198
Rosenberg, P. B., Lanctôt, K. L., Drye, L. T., Herrmann, N., Scherer, R. W., Bachman, D. L., Mintzer, J. E., & ADMET investigators (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08099 · Cited by 191 · cited 9×
“Brexpiprazole provoked treatment-emergent adverse events (TEAEs) in both studies, including headache, insomnia, urinary tract infection, and others.”
InfluentialBallard, C., Banister, C., Khan, Z., Cummings, J., Demos, G., Coate, B., Youakim, J. M., Owen, R., Stankovic, S., Tomkinson, E. B., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30039-5 · Cited by 190 · cited 1×
“Further follow-up through week 12 revealed no meaningful benefits for pimavanserin as compared to placebo (81).”
BackgroundFerrero, J., Williams, L., Stella, H., Leitermann, K., Mikulskis, A., O'Gorman, J., & Sevigny, J. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.002 · Cited by 189 · cited 1×
“In a first-in-human study (NCT01397539), a dose of 30 mg/kg demonstrated an acceptable safety and tolerability profile, although patients receiving 60 mg/kg of aducanumab experienced serious adverse events (SAEs) and symptomatic amyloid-related imaging abnormalities (ARIA) that resolved at weeks 8–15 (12).”
BackgroundSalameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188 · cited 1×
“GLP-1 has the ability to cross the BBB and may improve insulin signaling in the brain (42, 43).”
BackgroundSodium Oligomannate: First Approval
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01268-1 · Cited by 187
Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease
Herrmann, N., Ruthirakuhan, M., Gallagher, D., Verhoeff, N. P. L. G., Kiss, A., Black, S. E., & Lanctôt, K. L. (2019) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.05.002 · Cited by 169
Grossberg, G. T., Kohegyi, E., Mergel, V., Josiassen, M. K., Meulien, D., Hobart, M., Slomkowski, M., Baker, R. A., McQuade, R. D., & Cummings, J. L. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.09.009 · Cited by 169 · cited 3×
“In post-hoc studies, however, patients titrated to the maximal brexpiprazole dose of 2 mg/day indicated a benefit when compared to similarly titrated placebo patients (66).”
BackgroundHerrmann, N., Rothenburg, L. S., Black, S. E., Ryan, M., Liu, B. A., Busto, U. E., & Lanctôt, K. L. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b479 · Cited by 147 · cited 1×
“Another placebo-controlled crossover trial found that, in comparison to placebo, methylphenidate patients’ apathy was considerably improved (74).”
BackgroundTrial of pimavanserin in dementia-related psychosis
Tariot, P. N., Cummings, J. L., Soto-Martin, M. E., Ballard, C., Erten-Lyons, D., Sultzer, D. L., Devanand, D. P., Weintraub, D., McEvoy, B., Youakim, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034634 · Cited by 145
Assal, F., Alarcón, M., Solomon, E. C., Masterman, D., Geschwind, D. H., & Cummings, J. L. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1249 · Cited by 142 · cited 1×
“Previous research revealed that activation at the 5-HT2A receptor could possibly help with AD psychosis (78).”
BackgroundMintzer, J. E., Lanctôt, K. L., Scherer, R. W., Rosenberg, P. B., Herrmann, N., van Dyck, C. H., Padala, P. R., Brawman‐Mintzer, O., Porsteinsson, A. P., Lerner, A. J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3356 · Cited by 138 · cited 1×
“The NPI apathy score in those receiving methylphenidate decreased more from baseline to 6 months than in those taking placebo, and its safety was clearly proven in this experiment (76).”
BackgroundTeixeira, J. P., de Castro, A. A., Soares, F. V., da Cunha, E. F. F., & Ramalho, T. C. (2019) · Molecules · doi:10.3390/molecules24234410 · Cited by 121
Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
Lowe, S. L., Willis, B. A., Hawdon, A., Natanegara, F., Chua, L., Foster, J., Shcherbinin, S., Ardayfio, P., & Sims, J. R. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12112 · Cited by 120 · cited 1×
“It was observed that increasing the dose prolonged the mean terminal elimination half-life (34).”
BackgroundPharmacological interventions for apathy in Alzheimer's disease
Ruthirakuhan, M. T., Herrmann, N., Abraham, E. H., Chan, S., & Lanctôt, K. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012197.pub2 · Cited by 113 · cited 1×
“In recent research, methylphenidate has been considered to be an effective symptom-modifying drug (90).”
BackgroundHalpern, R., Seare, J., Tong, J., Hartry, A., Olaoye, A., & Aigbogun, M. S. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5030 · Cited by 110 · cited 1×
“Agitation is a prevalent symptom of dementia, affecting up to 70% of patients with AD during their illness (91).”
BackgroundZhang, C., Griciuc, A., Hudry, E., Wan, Y., Quinti, L., Ward, J., Forte, A. M., Shen, X., Ran, C., Elmaleh, D. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19641-2 · Cited by 99 · cited 1×
“a pro-neuroinflammatory state in APPSwedish-expressing Tg2576 mice (39).”
BackgroundMethylphenidate for Apathy and Functional Status in Dementia of the Alzheimer Type
Padala, P. R., Burke, W. J., Shostrom, V., Bhatia, S. C., Wengel, S. P., POTTER, J. F., & Petty, F. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181cabcf6 · Cited by 98 · cited 1×
“It was shown that methylphenidate was welltolerated and alleviated apathy in patients with AD in two openlabel studies (72, 73).”
BackgroundMethylphenidate treatment of negative symptoms in patients with dementia
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.2.231 · Cited by 96 · cited 1×
“It was shown that methylphenidate was welltolerated and alleviated apathy in patients with AD in two openlabel studies (72, 73).”
BackgroundReading, C. L., Ahlem, C. N., & Murphy, M. F. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0022 · Cited by 84 · cited 2×
“It has been demonstrated to reduce inflammation-driven ERK- and nuclear factor kappa-B (NF-κB)-stimulated inflammatory mediators, including tumor necrosis factor (TNF-α), without interfering with their homeostatic functions (50).”
BackgroundChang, Y.-F., Zhang, D., Hu, W.-M., Liu, D.-X., & Li, L. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.09.054 · Cited by 80 · cited 1×
“It also prevents apoptosis by reducing Bax expression caused by Aβ25 and enhancing Bcl2 expression decreased by Aβ2535 (45).”
BackgroundAbushakra, S., Porsteinsson, A., Scheltens, P., Sadowsky, C., Vellas, B., Cummings, J., Gauthier, S., Hey, J. A., Power, A., Wang, P., et al. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.26 · Cited by 75 · cited 1×
“Compared to tramiprosate, ALZ801 has better gastrointestinal tolerability and more stable plasma levels, resulting in higher brain penetration (18).”
BackgroundCannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
Liu, C. S., Chau, S. A., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2015) · CNS Drugs · doi:10.1007/s40263-015-0270-y · Cited by 72 · cited 1×
“CB2 receptors were engaged at the same time, reducing the generation of proinflammatory chemicals and removing Aβ plaques (62).”
BackgroundHey, J. A., Kocis, P., Hort, J., Abushakra, S., Power, A., Vyhnálek, M., Yu, J. Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 71 · cited 2×
“It and tramiprosate are both converted to 3-sulfo-propanic acid (3-SPA), which is present in the brain and inhibits Aβ42 aggregation (17).”
BackgroundAnti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J., Blennow, K., Johnson, K., Keeley, M., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P., & Vellas, B. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.14 · Cited by 71 · cited 5×
“Tau biology adds to the list of potentially relevant targets for DMT (89).”
BackgroundInfluentialSöllvander, S., Nikitidou, E., Gallasch, L., Zyśk, M., Söderberg, L., Sehlin, D., Lannfelt, L., & Erlandsson, A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1134-4 · Cited by 70 · cited 1×
“In addition, mAb158 was found to protect neurons and reduce the toxicity of Aβ-protofibrils in neuron-glia co-cultures of mice by counteracting the abnormal accumulation of these protofibrils in astrocytes (28).”
BackgroundThe psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT1A receptor
Markowitz, J. S., Markowitz, J. S., DeVane, C. L., Ramamoorthy, S., Zhu, H.-J., & Zhu, H.-J. (2009) · Die Pharmazie · doi:10.31083/ph.2009.8691 · Cited by 68
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate
van Dyck, C. H., Arnsten, A. F. T., Padala, P. R., Brawman‐Mintzer, O., Lerner, A. J., Porsteinsson, A. P., Scherer, R. W., Levey, A. I., Herrmann, N., Jamil, N., et al. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.04.026 · Cited by 55 · cited 1×
“Apathy in people with AD is thought to be caused by reduced dopaminergic neurotransmission (70).”
BackgroundPTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients
Wang, H.-Y., Pei, Z., Lee, K.-C., Lopez-Brignoni, E., Nikolov, B., Crowley, C. A., Marsman, M. R., Barbier, R., Friedmann, N., & Burns, L. H. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2020.6 · Cited by 45 · cited 4×
“Biomarkers of neuroinflammation in the CSF (YKL-40 and inflammatory cytokines) dropped by 5–14%, and the outcomes were similar in plasma (48).”
BackgroundInfluentialNeurodegenerative disorders—Searching for targets and new ways of diseases treatment
Abramov, A. Y., & Бачурин, С. О. (2021) · Medicinal Research Reviews · doi:10.1002/med.21794 · Cited by 45 · cited 1×
“Research progress on potentially effective neuroprotectors and therapeutic strategies that prevent the development of AD is stalled because of a lack of adequate understanding of the intricate mechanisms of neurodegeneration (7).”
BackgroundProfile of gantenerumab and its potential in the treatment of Alzheimer's disease
Nisticò, R., Novakovic, D., Feligioni, M., Scaccianoce, S., Piccinin, S., Mercuri, N. B., Nicoletti, F., Caruso, A., Schepisi, C., & Errico, F. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s53401 · Cited by 44
Portron, A., Jordan, P., Draper, K., Muenzer, C., Dickerson, D., van Iersel, T., & Hofmann, C. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.11.015 · Cited by 44 · cited 2×
“It showed that subcutaneous gantenerumab injections at rates of 5 and 15 s were well-tolerated in healthy volunteers, potentially allowing patients with AD or their caretakers to administer the drug at home (24).”
BackgroundMethylphenidate HCl: therapy for attention deficit hyperactivity disorder
Capp, P. K., Pearl, P. L., & Conlon, C. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.3.325 · Cited by 40 · cited 1×
“It inhibits the transporters of these neurotransmitters, resulting in an increase in dopamine and adrenaline levels in the synaptic cleft (67).”
BackgroundBallard, C., Youakim, J. M., Coate, B., & Stankovic, S. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.30 · Cited by 40 · cited 1×
“008) for pimavanserin and placebo, respectively, in this severe subgroup with a baseline Neuropsychiatric InventoryNursing Home Version psychosis score (NPI-NH-PS) ≥12 (n = 27 pimavanserin; n = 30 placebo) (82).”
BackgroundPharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers
Brazier, D., Perry, R., Keane, J., Barrett, K., & Elmaleh, D. R. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0549-5 · Cited by 31 · cited 1×
“7 ng and the associated inflammatory response (40).”
BackgroundRuthirakuhan, M. T., Herrmann, N., Gallagher, D., Andreazza, A. C., Kiss, A., Verhoeff, N. P. L. G., Black, S. E., & Lanctôt, K. L. (2019) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2019.100385 · Cited by 31
AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation
Khoury, R., Marx, C., Mirgati, S., Velury, D., Chakkamparambil, B., & Grossberg, G. T. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1882995 · Cited by 31 · cited 1×
“DM is the agent’s neuroactive ingredient (58).”
Effects of methylphenidate on the behavior of male 5xFAD mice
Schneider, F. W., Baldauf, K., Wetzel, W., & Reymann, K. G. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.11.006 · Cited by 26 · cited 1×
“Methylphenidate may benefit noncognitive, apathy-like behavior (as demonstrated by decreased exploration) in the 5xFAD mouse model, but it has little ability to enhance chronic Alzheimer’s typical learning and memory deficiencies (71).”
BackgroundIbuprofen and Alzheimer's disease.
Dökmeci, D. (2004) · PubMed · Cited by 25
Irizarry, M. C., Sims, J. R., Lowe, S. L., Nakano, M., Hawdon, A., Willis, B. A., Gonzales, C., Liu, P., Fujimoto, S., Dean, R. A., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.665 · Cited by 25
Reading, C. L., Frincke, J. M., & White, S. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032147 · Cited by 21
Serotonin and amyloid deposition: A link between depression and Alzheimer’s disease?
Gründer, G., & Cumming, P. D. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15269 · Cited by 12 · cited 1×
“Pimavanserin administration interfered with Aβ deposition by altering the balance between two 5HT2A signaling pathways that were antagonists of Gq/11 signaling and agonists of Gαi1 signaling, according to the findings (80).”
Background
Research works printed but not linked: 16
- World Alzheimer's Day. Caring for the Elderly, Please Pay Attention to Alzheimer's Disease. Chinese Center for Disease Control and Prevention (2019).
- Jinzhou T Hengge X Luning W. Chinese guidelines for the diagnosis and treatment of Alzheimer's Disease (Version 2020). Chin J Gerontol. (2021) 40: 269– 83. 10.3760/cma.j.issn.0254-9026.2021.03.00135381646 · doi:10.3760/cma.j.issn.0254-9026.2021.03.00135381646
- America PRaMo. Researching Alzheimer's Medicines: Setbacks and Stepping Stones, 2012. PhRMA (2016).
- Biogen. Aduhelm™ Instruction. FDA (2021).
- Cavazzoni P. Fda's Decision to Approve New Treatment for Alzheimer's Disease. FDA (2021).35815585
- Dutton G. New Drug Approval Could Be on Horizon for Alzheimer's after 17-Year Drought. BioSpace (2021).
- Lecanemab (Also Called Ban2401). ALS News Today (2021).
- ALZFORUM. Lecanemab Sweeps up Toxic Aβ Protofibrils, Catches Eyes of Trialists (2021).
- MS MW. Simufilam (Pti-125). Alzheimer's News Today (2022).
- Shanghai Green Valley Pharmaceuticals Co. L. Sodium Oligomannate Capsules: Chinese Prescribing Information. ALZFORUM (2020).
- ALZFORUM. Fits and Starts: Trial Results from the Ctad Conference (2018).
- Jacobson M. Advance-1 Phase 2/3 Trial of Axs-05 in Alzheimer's Disease Agitation Topline Results. Axsome (2020).
- US. FDA Drug Approval Package: Nuedexta (Dextromethorphan Hydrobromide and Quinidine Sulfate) Capsules. CISION (2011).
- Inc AP. Avanir Pharmaceuticals Announces Initiation of Phase Iii Trial of Avp-786 for Agitation in Patients with Alzheimer's Disease (2015).
- Avanir. Avanir Pharmaceuticals Announces Initiation of Phase Iii Trial of Avp-786 for Agitation in Patients With Alzheimer's Disease. (2015).
- Verghese C Abdijadid S. Methylphenidate. StatPearls (2021). 29494058
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alzheimer’s Disease: The Past, Present, and Future of a Globally Progressive Disease
Vejandla, B., Savani, S., Appalaneni, R., Veeravalli, R. S., & Gude, S. S. (2024) · Cureus · doi:10.7759/cureus.51705 · Cited by 64
Liu, W., Li, Y., Zhao, T., Gong, M., Wang, X., Zhang, Y., Xu, L., Li, W., Li, Y., & Jia, J. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102534 · Cited by 46
The Application of Deuteration Strategy in Drug Design
Chen, Y., & Du, Y. (2024) · ChemMedChem · doi:10.1002/cmdc.202400836 · Cited by 39
The Vascular-Immune Hypothesis of Alzheimer’s Disease
Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 37
“Additional clinical treatment effects of lecanemab are yet to be determined and a number of other anti-βA drugs remain under investigation [34].”
Background
Metadata
- Authors
- Cao, Y., Yu, F., Lyu, Y., & Lu, X.
- Affiliations
- China Pharmaceutical University (CN)
- Fudan University (CN)
- Anhui Medical University (CN)
- Corresponding author
- Lyu, Yi
- Lu, Xianfu
- ORCID
- Lu, Xianfu
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2022-11-15
- Volume
- 13
- Pages
- 1034243-1034243
- ISSN
- 1664-2295 (ISSN-L)
- PMC
- PMC9706102
- OpenAlex
- W4309212128
- Cited by
- 26
- References
- 69
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 9 · 2023: 4
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Neurology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, late-stage clinical trials, disease-modifying therapy, symptomatic treatment, gantenerumab, aducanumab, donanemab, lecanemab, semaglutide, drug repurposing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.